DEA registration loss after Texas-license action — the § 824(a)(3) trigger

How DEA registration depends on state authority

Under 21 U.S.C. § 823 and DEA regulations at 21 C.F.R. § 1306.03, a DEA registration to handle controlled substances is contingent on the registrant's state authority to do so. The DEA regulatory structure piggybacks on state professional regulation; federal authority is generally not granted where state authority is absent.

When the state authority is removed — by Texas Medical Board suspension, DPS controlled-substances permit revocation, license surrender, or comparable action — the foundation for the DEA registration is removed. The DEA can then revoke or suspend the federal registration under § 824(a)(3).

The § 824(a) grounds for revocation

§ 824(a) sets out the grounds:

1. Materially false or fraudulent application.
2. Conviction of a felony relating to controlled substances or List I chemicals.
3. Loss of state authority to handle controlled substances (the focus of this article).
4. Exclusion from participation in any Medicare or state health-care program.
5. Inconsistent action with public interest under the § 823(f) factors.

§ 824(a)(3) is the most automatic ground. The triggering event — loss of state authority — is largely a factual question. If state authority is gone, the federal registration almost always follows.

What "state authority" means under DEA practice

The DEA construes "state authority" broadly to include any state credential needed to handle controlled substances at the registrant's level of practice. For a Texas-licensed physician, that includes:

• The medical license issued by the Texas Medical Board.
• The Texas DPS controlled-substances registration.
• The DEA registration itself is downstream of these.

Loss of any required state credential supports DEA action. A medical license suspended by TMB while a controlled-substances permit remains active is still a loss of state authority — the registrant cannot lawfully practice and therefore cannot lawfully handle controlled substances.

The administrative process: from show cause to ALJ

DEA registration actions proceed through:

1. Order to Show Cause. Issued by the DEA. Sets forth the basis for the proposed action and gives the registrant 30 days to request a hearing.
2. Administrative hearing. Conducted by a DEA Administrative Law Judge. Discovery, expert testimony, and cross-examination are available.
3. ALJ recommended decision. Reviewed by the DEA Administrator.
4. Final agency decision. Subject to judicial review under the Administrative Procedure Act and 21 U.S.C. § 877 (direct review in the courts of appeals).

The hearing process can be expedited where the agency seeks immediate suspension based on the § 824(d) "imminent danger" standard.

Texas-specific triggers

Texas Medical Board orders

Suspension, revocation, voluntary surrender, or imposition of conditions that restrict controlled-substance authority.

Texas State Board of Pharmacy orders

For registered pharmacists and pharmacies.

Texas Department of Public Safety actions

DPS controlled-substances registration suspension or revocation.

Voluntary surrender

A registrant who surrenders a state credential to avoid disciplinary action typically still triggers § 824(a)(3) review, because the loss of authority is the operative fact regardless of mechanism.

Defense strategy: synchronizing state and federal proceedings

The most consequential defense move is to address state and federal proceedings as a coordinated whole rather than sequentially. Specific steps:

1. Identify the timeline early. A pending state proceeding usually predicts a DEA action. Counsel should not wait for the OSC to plan.
2. Avoid unforced surrenders. A voluntary surrender of state credentials to short-circuit a TMB matter can trigger § 824(a)(3) action that a contested hearing might have prevented or modified.
3. Negotiate state outcomes that preserve federal viability. Settled state agreements with conditions (CME, monitoring, restricted prescribing) generally preserve state authority and avoid § 824(a)(3) exposure.
4. Build the public-interest record. Even in § 824(a)(3) cases, the DEA can consider mitigating evidence under the § 823(f) factors. Patient outcomes, remedial training, and absence of diversion all matter.

Consequences and reinstatement

A DEA revocation has broad effects: the practitioner cannot prescribe controlled substances anywhere in the United States, may face hospital privilege loss, will likely face insurance-credentialing consequences, and may face Medicare exclusion under separate authority.

Reinstatement after a § 824(a)(3) revocation typically requires restoration of state authority first. Once the state credential is back in good standing, the registrant can apply for a new DEA registration. The DEA will conduct a public-interest review and may impose conditions on reinstatement.

Parallel proceeding strategy in detail

The defining feature of a § 824(a)(3) case is the parallel proceeding structure. There are typically three concurrent tracks:

The state administrative track

Before the Texas Medical Board, the Texas State Board of Pharmacy, or the Texas Department of Public Safety. The hearing officer or board reviews the alleged conduct, the practitioner's response, and any expert testimony, then issues an order.

The federal administrative track

Before the DEA. Triggered by the state action. Hearings before an ALJ with a recommended decision to the Administrator.

The criminal track (where applicable)

If the underlying conduct involves alleged controlled-substance diversion or fraud, a parallel criminal case may proceed in state or federal court.

Counsel should map the three tracks and identify dependencies. State board action drives the DEA action. Criminal exposure can drive Fifth Amendment considerations in the administrative hearings. The sequence of events matters.

The "interest of public service" factors

Even in § 824(a)(3) cases where the basis for revocation is state-authority loss, the DEA considers the public-interest factors of § 823(f). The agency has discretion to impose conditions short of full revocation. The five factors:

1. The recommendation of the appropriate State licensing board.
2. The applicant's experience in dispensing controlled substances.
3. The applicant's conviction record under federal or State laws relating to controlled substances.
4. Compliance with applicable State, federal, or local laws relating to controlled substances.
5. Such other conduct which may threaten the public health and safety.

A practitioner who can establish remediation, compliance training, and community-confidence indicators can sometimes obtain a conditional registration or a less-than-full revocation. The defense should marshal evidence on each factor.

Reinstatement procedure after revocation

After a § 824(a)(3) revocation, the practitioner who wants to resume controlled-substance prescribing must rebuild authority from the bottom up. The typical sequence:

1. Restore state authority. Address the underlying state-licensing issue. This may involve a TMB reinstatement application with proof of remediation, completion of any required CME, and a record of compliance.
2. Restore DPS controlled-substances permit. Once state professional licensing is restored, the DPS controlled-substances permit can be re-applied for.
3. Apply for new DEA registration. With state authority restored, the practitioner can submit a Form 224 application. The DEA reviews under the § 823(f) public-interest factors and may impose conditions.
4. Demonstrate ongoing compliance. The first 12-24 months after reinstatement typically involve enhanced monitoring, with detailed dispensing records, attestation requirements, and possible audits.

The reinstatement timeline is long — typically 6-18 months from state restoration to functional DEA registration. Practitioners contemplating settlement of the original state matter should consider whether the path back is worth the cost of the disciplinary record.

Engaging counsel and next steps

DEA registration cases require parallel administrative-defense work alongside any state board defense and any criminal-case defense. The three-track structure demands coordinated strategy from day one.

The DFW criminal-defense landscape has evolved substantially in the post-pandemic period. Caseloads have shifted, prosecutor staffing has changed, and several core statutes have been amended by the 88th and 89th Legislatures. Counsel should periodically refresh the working knowledge base — bar CLE materials, the Texas District & County Attorneys Association publications, and the Court of Criminal Appeals' recent opinions are reliable starting points.

For practitioners facing a § 824 administrative action, the realistic outcome depends on the strength of the underlying state matter, the quality of the remediation record, and the public-interest narrative. Each can be developed with counsel's help, but each requires substantial preparation.

For potential clients in Collin, Dallas, Denton, Tarrant, Rockwall, Kaufman, Ellis, Johnson, and Hunt counties, consultations at L and L Law Group are free and confidential. The earlier counsel is engaged, the more strategic options remain open. Many of the procedural levers discussed in this article narrow or close as the case progresses; an attorney engaged at the magistrate stage has tools that an attorney engaged at sentencing does not.

Final framework for § 824(a)(3) defense

The defense framework for § 824(a)(3) cases:

1. Map all three tracks early. State licensing, federal DEA administrative, and any criminal exposure.
2. Preserve state authority where possible. Settlements that preserve the state license generally avoid § 824(a)(3) automatic triggers.
3. Build the public-interest record. Remediation, training, monitoring, patient outcomes.
4. Coordinate the timeline. Hearings, exhibits, and witnesses should be aligned across the three tracks.
5. Plan for the long road. Reinstatement, if needed, takes 12-24 months and requires sustained compliance.

Hearing-strategy considerations

The DEA administrative hearing is a real evidentiary proceeding with witnesses, exhibits, and cross-examination. Effective hearing strategy includes:

1. Identifying which witnesses to call (treating providers, character witnesses, expert witnesses on standard of care).
2. Preparing for cross-examination of DEA agents and investigators.
3. Building the public-interest exhibits: CME completion certificates, mentor or monitor letters, patient-outcome data.
4. Coordinating with parallel state and criminal proceedings to avoid contradictory positions.
5. Considering settlement options — the DEA can resolve cases via Memorandum of Agreement (MOA) with conditions short of full revocation.

The MOA pathway is often the realistic optimal outcome where the underlying state matter is resolved on a settlement basis. Counsel should evaluate MOA terms carefully — the conditions, monitoring period, and reporting obligations can extend for years and have material practice consequences.

References

1. 21 U.S.C. § 824 (denial, revocation, or suspension of registration), law.cornell.edu/uscode/text/21/824.
2. 21 U.S.C. § 823 (registration requirements), law.cornell.edu/uscode/text/21/823.
3. 21 U.S.C. § 877 (judicial review), law.cornell.edu/uscode/text/21/877.
4. 21 C.F.R. § 1306.03 (state authority for prescribing).